Transcriptomic Classification of Non-muscle Invasive Bladder Cancer and its Clinical and Prognostic Implication

We are conducting a comprehensive transcriptomic analysis of non-muscle invasive bladder cancer (NMIBC) and examining associations of molecular subtypes with clinical treatment and prognostic outcomes at 5 years (60 months) post-diagnosis in the Be-Well prospective cohort study of 1,472 NMIBC patients. Our central hypothesis is that high-resolution of molecular subtypes could unveil NMIBC heterogeneity with potential therapeutic and prognostic implications for clinical management. Our aims are to: identify molecular subtypes of NMIBC based on transcriptomic analysis and to evaluate subtype-specific risk factors; examine associations of molecular subtypes of NMIBC with prognostic outcomes and to develop NMIBC-specific gene signatures for risk stratification; determine associations of molecular subtypes of NMIBC with BCG outcomes including treatment failure and side effects.

0